Abstract
Purpose: To evaluate the current status of stereotactic body radiotherapy (SBRT) for early staged non-small cell lung cancer (NSCLC) at main cancer hospitals in China. Methods and Materials: The questionnaire was sent by mail and email to 21 hospitals, which include the patient enrollment, treatment technique, dose and fractionation, quality control, disease control and side effects. Results: Nineteen hospitals responded. It was found that SBRT has been used for early staged NSCLC in most of the hospitals participating in the survey. The patient characteristics and techniques were relatively consistent, but there were many controversies regarding dose fractionation and quality control. Conclusions: SBRT for early staged NSCLC has been applied at main cancer hospitals in China. However, considerable variation exists. The establishment of clinical guidelines and standardized quality control are crucial for further improvement.
Highlights
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that delivers very high dose radiation in a limited number of fractions precisely to a tumor while minimizing dose to adjacent normal tissue
In a recent survey of SBRT use in the United States, 63.9% of evaluable respondents reported using SBRT in their practice [6]
Our survey found that SBRT is commonly offered at the main cancer centers in China as treatment for early staged non-small cell lung cancer (NSCLC)
Summary
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that delivers very high dose radiation in a limited number of fractions precisely to a tumor while minimizing dose to adjacent normal tissue. It will allow the Chinese community to become aware of its own successes, inconsistencies and variations, and it will allow the rest of the world to understand modern Chinese practice and the manner in which that practice might be able to be aligned with practice elsewhere. With this purpose, we conducted a survey of radiation oncologists from main cancer centers in China regarding their SBRT usage for early staged non-small cell lung cancer (NSCLC)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
